CTI’s pixantrone gets kicked to the dirt again, but FDA gives some hope
This article was originally published in Scrip
Executive Summary
The US FDA again rejected Cell Therapeutics' application for pixantrone as a single-agent treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma – this time denying a dispute appeal request filed in December to conclude that the efficacy of the drug has been demonstrated, the company revealed.